| AU4645697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
| AU762220B2 (en) | 1998-05-28 | 2003-06-19 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | AAV5 vector and uses thereof |
| US7718354B2 (en) | 2001-03-02 | 2010-05-18 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
| US20040121309A1 (en) | 2002-12-06 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues |
| US7666588B2 (en) | 2001-03-02 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
| US7226739B2 (en) | 2001-03-02 | 2007-06-05 | Isis Pharmaceuticals, Inc | Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations |
| US20030027135A1 (en) | 2001-03-02 | 2003-02-06 | Ecker David J. | Method for rapid detection and identification of bioagents |
| US8073627B2 (en) | 2001-06-26 | 2011-12-06 | Ibis Biosciences, Inc. | System for indentification of pathogens |
| US7217510B2 (en) | 2001-06-26 | 2007-05-15 | Isis Pharmaceuticals, Inc. | Methods for providing bacterial bioagent characterizing information |
| CA3159060C (en)* | 2001-11-13 | 2023-05-16 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| ES2717377T3 (en) | 2001-12-17 | 2019-06-20 | Univ Pennsylvania | Sequences of serotype 8 of adeno-associated virus (AAV), vectors containing them and uses thereof |
| WO2003052052A2 (en)* | 2001-12-17 | 2003-06-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| ES2280694T3 (en)* | 2002-04-29 | 2007-09-16 | The Trustees Of The University Of Pennsylvania | METHOD FOR DIRECT EXTRACTION AND AMPLIFICATION OF INTEGRATED VIRUSES OF TISSUE CELLULAR DNA. |
| US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
| US7220577B2 (en)* | 2002-08-28 | 2007-05-22 | University Of Florida Research Foundation, Inc. | Modified AAV |
| EP1578399A4 (en) | 2002-12-06 | 2007-11-28 | Isis Pharmaceuticals Inc | PROCESS FOR THE RAPID IDENTIFICATION OF PATHOGENS IN ANIMAL AND MAN |
| US8046171B2 (en) | 2003-04-18 | 2011-10-25 | Ibis Biosciences, Inc. | Methods and apparatus for genetic evaluation |
| US8057993B2 (en) | 2003-04-26 | 2011-11-15 | Ibis Biosciences, Inc. | Methods for identification of coronaviruses |
| US7964343B2 (en) | 2003-05-13 | 2011-06-21 | Ibis Biosciences, Inc. | Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
| US8158354B2 (en) | 2003-05-13 | 2012-04-17 | Ibis Biosciences, Inc. | Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
| US8927269B2 (en) | 2003-05-19 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Avian adenoassociated virus and uses thereof |
| EP1633772B1 (en)* | 2003-06-19 | 2015-11-18 | Avigen, Inc. | Aav virions with decreased immunoreactivity and uses therefor |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| AU2010201278B2 (en)* | 2003-09-01 | 2012-11-15 | Academisch Medisch Centrum | AAV vectors for in vivo gene therapy of rheumatoid arthritis |
| NZ545656A (en)* | 2003-09-01 | 2009-02-28 | Amc Amsterdam | AAV vectors for in vivo gene therapy of rheumatoid arthritis |
| US20120122099A1 (en) | 2003-09-11 | 2012-05-17 | Rangarajan Sampath | Compositions for use in identification of bacteria |
| US8546082B2 (en) | 2003-09-11 | 2013-10-01 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
| US8097416B2 (en) | 2003-09-11 | 2012-01-17 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
| AU2011250849B2 (en)* | 2003-09-30 | 2013-09-12 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor |
| US7906111B2 (en)* | 2003-09-30 | 2011-03-15 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor |
| WO2005056807A2 (en) | 2003-12-04 | 2005-06-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Bovine adeno-associated viral (baav) vector and uses thereof |
| US7666592B2 (en) | 2004-02-18 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
| US8119336B2 (en) | 2004-03-03 | 2012-02-21 | Ibis Biosciences, Inc. | Compositions for use in identification of alphaviruses |
| CA2563500C (en)* | 2004-04-28 | 2016-06-28 | The Trustees Of The University Of Pennsylvania | Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost |
| EP1742668B1 (en)* | 2004-04-28 | 2011-02-09 | The Trustees of The University of Pennsylvania | Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations |
| JP4810533B2 (en) | 2004-05-24 | 2011-11-09 | アイビス バイオサイエンシズ インコーポレイティッド | Mass spectrometry using selective ion filtration by digital thresholding. |
| US20050266411A1 (en) | 2004-05-25 | 2005-12-01 | Hofstadler Steven A | Methods for rapid forensic analysis of mitochondrial DNA |
| US7811753B2 (en) | 2004-07-14 | 2010-10-12 | Ibis Biosciences, Inc. | Methods for repairing degraded DNA |
| WO2006073496A2 (en)* | 2004-07-30 | 2006-07-13 | Targeted Genetics Corporation | Recombinant aav based vaccine methods |
| US7309589B2 (en)* | 2004-08-20 | 2007-12-18 | Vironix Llc | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing |
| WO2006135400A2 (en) | 2004-08-24 | 2006-12-21 | Isis Pharmaceuticals, Inc. | Methods for rapid identification of recombinant organisms |
| WO2006037996A1 (en)* | 2004-10-05 | 2006-04-13 | Merz Pharma Gmbh & Co. Kgaa | Novel cyclic and acyclic propenones for treating cns disorders |
| CA2600184A1 (en) | 2005-03-03 | 2006-09-08 | Isis Pharmaceuticals, Inc. | Compositions for use in identification of adventitious viruses |
| US8084207B2 (en) | 2005-03-03 | 2011-12-27 | Ibis Bioscience, Inc. | Compositions for use in identification of papillomavirus |
| EP4282956A3 (en) | 2005-04-07 | 2024-03-13 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
| WO2006119432A2 (en)* | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| EP1904655A2 (en) | 2005-07-21 | 2008-04-02 | Isis Pharmaceuticals, Inc. | Methods for rapid identification and quantitation of nucleic acid variants |
| JP2009519010A (en)* | 2005-11-28 | 2009-05-14 | アイビス バイオサイエンシズ インコーポレイティッド | Composition for use in the identification of foreign contaminants |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| CN101528916B (en) | 2006-04-28 | 2013-09-04 | 宾夕法尼亚大学托管会 | Scalable production method for AAV |
| GB2437893A (en)* | 2006-07-25 | 2007-11-07 | Celladon Corp | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy |
| AU2007353877B2 (en) | 2006-09-14 | 2012-07-19 | Ibis Biosciences, Inc. | Targeted whole genome amplification method for identification of pathogens |
| EP2126132B1 (en) | 2007-02-23 | 2013-03-20 | Ibis Biosciences, Inc. | Methods for rapid foresnsic dna analysis |
| US9611302B2 (en) | 2007-04-09 | 2017-04-04 | University Of Florida Research Foundation, Inc. | High-transduction-efficiency RAAV vectors, compositions, and methods of use |
| US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| PL2191001T4 (en) | 2007-04-09 | 2017-01-31 | University Of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
| US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
| EP2058401A1 (en)* | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| CA2762118A1 (en) | 2008-05-20 | 2010-01-28 | Eos Neuroscience, Inc. | Vectors for delivery of light-sensitive proteins and methods of use |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| EP2344893B1 (en) | 2008-09-16 | 2014-10-15 | Ibis Biosciences, Inc. | Microplate handling systems and methods |
| US8148163B2 (en) | 2008-09-16 | 2012-04-03 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
| EP2349549B1 (en) | 2008-09-16 | 2012-07-18 | Ibis Biosciences, Inc. | Mixing cartridges, mixing stations, and related kits, and system |
| EP2396803A4 (en) | 2009-02-12 | 2016-10-26 | Ibis Biosciences Inc | Ionization probe assemblies |
| CN102439157B (en) | 2009-04-30 | 2015-09-16 | 宾夕法尼亚大学托管会 | Comprise the target conducting airways cell composition of adeno associated virus construct |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| WO2010143761A1 (en)* | 2009-06-12 | 2010-12-16 | (주)바이오니아 | Method for quickly detecting infectious microorganisms in unknown sample |
| WO2011008972A1 (en) | 2009-07-17 | 2011-01-20 | Ibis Biosciences, Inc. | Systems for bioagent identification |
| US8950604B2 (en) | 2009-07-17 | 2015-02-10 | Ibis Biosciences, Inc. | Lift and mount apparatus |
| WO2011041502A1 (en) | 2009-10-01 | 2011-04-07 | The Trustees Of The University Of Pennsylvania | Aav vectors expressing sec1o for treating kidney damage |
| EP3225695A1 (en) | 2009-10-15 | 2017-10-04 | Ibis Biosciences, Inc. | Multiple displacement amplification |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| CN102869779A (en) | 2010-03-29 | 2013-01-09 | 宾夕法尼亚大学托管会 | Pharmacologically induced transgene ablation system |
| EP3567106A1 (en) | 2010-04-23 | 2019-11-13 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| US9546369B2 (en) | 2010-04-23 | 2017-01-17 | University Of Massachusetts | Multicistronic expression constructs |
| CA2833912C (en) | 2010-04-23 | 2021-09-21 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
| CA3128549A1 (en) | 2010-07-12 | 2012-01-19 | Universitat Autonoma De Barcelona | Gene therapy composition for use in diabetes treatment |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| WO2012145572A1 (en) | 2011-04-20 | 2012-10-26 | The Trustees Of The University Of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
| US9226976B2 (en) | 2011-04-21 | 2016-01-05 | University Of Massachusetts | RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
| BR112013027120B1 (en) | 2011-04-22 | 2022-02-01 | The Regents Of The University Of California | Recombinant adeno-associated virus virion (raav), its use, pharmaceutical composition and recombinant adeno-associated virus virion 2 (raav2) |
| EP3795581A3 (en)* | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| US20130136729A1 (en)* | 2011-11-11 | 2013-05-30 | University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group | Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors |
| EP2814958B1 (en)* | 2012-02-17 | 2019-08-07 | The Children's Hospital of Philadelphia | Aav vector compositions and methods for gene transfer to cells, organs and tissues |
| WO2013130393A1 (en)* | 2012-02-28 | 2013-09-06 | Cornell University | Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation |
| WO2013154744A1 (en)* | 2012-04-13 | 2013-10-17 | Cornell University | Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction |
| US10294281B2 (en) | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
| EP2692868A1 (en) | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
| JP6387350B2 (en) | 2012-09-28 | 2018-09-05 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Adeno-associated virus vector targeting oligodendrocytes |
| ES2741502T3 (en) | 2013-02-08 | 2020-02-11 | Univ Pennsylvania | AAV8 capsid modified for gene transfer for retinal therapies |
| SI3889173T1 (en) | 2013-02-15 | 2023-11-30 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
| US8957044B2 (en) | 2013-03-01 | 2015-02-17 | Wake Forest University Health Sciences | Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) |
| LT2984166T (en) | 2013-03-15 | 2020-08-10 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS FOR THE TREATMENT OF MPSI |
| WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
| ES2897508T3 (en) | 2013-05-31 | 2022-03-01 | Univ California | Adeno-associated virus variants and methods of using them |
| KR20220041963A (en) | 2013-07-22 | 2022-04-01 | 더 칠드런스 호스피탈 오브 필라델피아 | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| DK3099333T3 (en) | 2014-01-31 | 2021-02-01 | Univ Temple | BAG3 AS A GOAL FOR THE TREATMENT OF HEART FAILURE |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| US10072251B2 (en) | 2014-02-19 | 2018-09-11 | University Of Massachusetts | Recombinant AAVS having useful transcytosis properties |
| LT3116900T (en) | 2014-03-09 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS FOR USE IN THE TREATMENT OF ORNITINE TRANSCARBAMYLASE (OTC) FAILURE |
| CN106414474B (en) | 2014-03-17 | 2021-01-15 | 阿德夫拉姆生物技术股份有限公司 | Compositions and methods for enhanced gene expression in cone cells |
| EP3750907A3 (en) | 2014-03-18 | 2021-04-28 | University of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
| SG10201912968WA (en) | 2014-03-21 | 2020-02-27 | Genzyme Corp | Gene therapy for retinitis pigmentosa |
| EP2933335A1 (en) | 2014-04-18 | 2015-10-21 | Genethon | A method of treating peripheral neuropathies and motor neuron diseases |
| JP6741590B2 (en) | 2014-04-25 | 2020-08-19 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | LDLR variants for lowering cholesterol levels and their use in compositions |
| WO2015164723A1 (en) | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| US10975391B2 (en) | 2014-04-25 | 2021-04-13 | University Of Massachusetts | Recombinant AAV vectors useful for reducing immunity against transgene products |
| WO2015175639A1 (en) | 2014-05-13 | 2015-11-19 | The Trustees Of The University Of Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
| US10689653B2 (en) | 2014-06-03 | 2020-06-23 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP2960336A1 (en) | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| DK3164394T3 (en) | 2014-07-03 | 2020-05-04 | Univ Texas | GLS1 INHIBITORS FOR TREATMENT OF DISEASES |
| EP4012035B1 (en) | 2014-09-16 | 2024-11-06 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
| PT4012035T (en) | 2014-09-16 | 2025-02-11 | Genzyme Corp | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| EP3795580A1 (en) | 2014-10-03 | 2021-03-24 | University of Massachusetts | High efficiency library-identified aav vectors |
| AU2015335923B2 (en) | 2014-10-21 | 2021-04-29 | University Of Massachusetts | Recombinant AAV variants and uses thereof |
| HK1243922A1 (en) | 2014-11-05 | 2018-07-27 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| KR102584655B1 (en) | 2014-11-14 | 2023-10-06 | 보이저 테라퓨틱스, 인크. | Modulatory polynucleotides |
| RU2716422C2 (en) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| HK1245326A1 (en) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| WO2016110518A1 (en) | 2015-01-07 | 2016-07-14 | Universitat Autònoma De Barcelona | Single-vector gene construct comprising insulin and glucokinase genes |
| HK1246815A1 (en) | 2015-01-16 | 2018-09-14 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
| CN107646052A (en) | 2015-01-20 | 2018-01-30 | 建新公司 | For characterizing the analytical supercentrifugation of recombinant virus particle |
| US20180030096A1 (en)* | 2015-02-03 | 2018-02-01 | University Of Florida Research Foundation, Inc. | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof |
| EP3256487A4 (en) | 2015-02-09 | 2018-07-18 | Duke University | Compositions and methods for epigenome editing |
| IL296466B2 (en) | 2015-02-10 | 2024-11-01 | Genzyme Corp | Increased transmission of viral particles to the striatum and cortex |
| HK1247641A1 (en) | 2015-02-10 | 2018-09-28 | Genzyme Corporation | VARIANT RNAi |
| EP3256170B1 (en) | 2015-02-13 | 2020-09-23 | University of Massachusetts | Compositions and methods for transient delivery of nucleases |
| BR112017018846A2 (en) | 2015-03-02 | 2018-07-31 | Adverum Biotechnologies, Inc. | compositions and methods for intravitreal delivery of polynucleotides to retinal cones. |
| JP2018509164A (en) | 2015-03-10 | 2018-04-05 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Recombinant Glut1 adeno-associated virus vector construct and method for restoring Glut1 expression |
| WO2016154344A1 (en) | 2015-03-24 | 2016-09-29 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
| TWI707951B (en) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | Production of oversized adeno-associated vectors |
| WO2016172155A1 (en) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
| CA3021949C (en) | 2015-04-24 | 2023-10-17 | University Of Massachusetts | Modified aav constructs and uses thereof |
| US20180110877A1 (en) | 2015-04-27 | 2018-04-26 | The Trustees Of The University Of Pennsylvania | DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| WO2016200543A2 (en) | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-inluenza antibodies and methods of use thereof |
| JP6985250B2 (en) | 2015-05-16 | 2021-12-22 | ジェンザイム・コーポレーション | Gene editing of deep intron mutations |
| US10799566B2 (en) | 2015-06-23 | 2020-10-13 | The Children's Hospital Of Philadelphia | Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues |
| EP3325018B1 (en) | 2015-07-22 | 2025-01-15 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
| KR102745604B1 (en) | 2015-08-06 | 2024-12-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | GLP-1 and its use in compositions for the treatment of metabolic diseases |
| WO2017035416A2 (en) | 2015-08-25 | 2017-03-02 | Duke University | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases |
| AU2016315699B2 (en) | 2015-08-31 | 2021-09-09 | The Trustees Of The University Of Pennsylvania | AAV-EPO for treating companion animals |
| HK1251482A1 (en) | 2015-09-24 | 2019-02-01 | 宾夕法尼亚州大学信托人 | Composition and method for treating complement-mediated disease |
| DK3356390T3 (en) | 2015-09-28 | 2021-04-12 | Univ North Carolina Chapel Hill | METHODS AND COMPOSITIONS FOR VIRUS VECTORS AVOIDING ANTIBODIES |
| US11273227B2 (en) | 2015-10-09 | 2022-03-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods useful in treating Stargardt's disease and other ocular disorders |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| CA3002980A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| EP3364997B1 (en) | 2015-10-22 | 2024-01-17 | University of Massachusetts | Aspartoacylase gene therapy in the treatment of canavan disease |
| CN108779167A (en) | 2015-10-28 | 2018-11-09 | 宾夕法尼亚州大学信托人 | Intrathecal application adeno-associated virus vector is used for gene therapy |
| WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| SG11201803098VA (en) | 2015-10-30 | 2018-05-30 | Nbe Therapeutics Ag | Anti-ror1 antibodies |
| EP3384035A4 (en) | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
| FR3044926B1 (en) | 2015-12-09 | 2020-01-31 | Genethon | EFFICIENT GENE THERAPY TOOLS FOR JUMPING DYSTROPHIN EXON 53 |
| ES2934848T3 (en) | 2015-12-11 | 2023-02-27 | Univ Pennsylvania | Scalable purification method for AAV8 |
| US11028372B2 (en) | 2015-12-11 | 2021-06-08 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAVRH10 |
| US11098286B2 (en) | 2015-12-11 | 2021-08-24 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV9 |
| CA3008142A1 (en) | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
| US11015173B2 (en) | 2015-12-11 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV1 |
| WO2017106345A1 (en) | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Composition for treatment of crigler-najjar syndrome |
| RU2762747C2 (en) | 2015-12-14 | 2021-12-22 | Зе Трастис Оф Зе Юниверсити Оф Пенсильвания | Gene therapy of ophthalmic disorders |
| MX2018007330A (en) | 2015-12-15 | 2019-03-14 | Genzyme Corp | Adeno-associated viral vectors for treating mucolipidosis type ii. |
| NZ743251A (en) | 2015-12-22 | 2025-03-28 | Univ Texas | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
| MX2018008926A (en) | 2016-01-20 | 2019-01-10 | Scripps Research Inst | Ror1 antibody compositions and related methods. |
| HRP20221089T1 (en) | 2016-02-01 | 2022-11-25 | Bioverativ Therapeutics Inc. | OPTIMIZED FACTOR VIII GENES |
| CA3011939A1 (en)* | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| SG11201806270XA (en) | 2016-02-03 | 2018-08-30 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
| WO2017139643A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| US10729789B2 (en)* | 2016-03-01 | 2020-08-04 | University Of Virginia Patent Foundation | Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells |
| US11207426B2 (en) | 2016-04-05 | 2021-12-28 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOS CIRCUIT SYSTEMS |
| JP7171439B2 (en) | 2016-04-15 | 2022-11-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Gene therapy for treating mucopolysaccharidosis type II |
| WO2017180861A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsulvania | Gene therapy for treating hemophilia b |
| CA3019423A1 (en)* | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Novel aav8 mutant capsids and compositions containing same |
| EP3452103A1 (en) | 2016-04-15 | 2019-03-13 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| CA3019425A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia a |
| WO2017184463A1 (en) | 2016-04-17 | 2017-10-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods useful for prophylaxis of organophosphates |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| GB201608046D0 (en)* | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| DK3445773T5 (en) | 2016-05-13 | 2024-09-09 | 4D Molecular Therapeutics Inc | Adeno-associated virus variant capsids and methods of using the same |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| RU2764587C2 (en) | 2016-05-18 | 2022-01-18 | Вояджер Терапьютикс, Инк. | Methods and compositions for treatment of huntington's chorea |
| US11158076B2 (en) | 2016-06-08 | 2021-10-26 | Sony Corporation | Imaging control device and method, and vehicle |
| WO2017218852A1 (en) | 2016-06-15 | 2017-12-21 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| US20190240353A1 (en) | 2016-07-05 | 2019-08-08 | University Of Massachusetts | Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma |
| BR112019000171A2 (en) | 2016-07-08 | 2019-10-01 | Univ Pennsylvania | methods and compositions for treating disorders and diseases involving rdh12 |
| WO2018017754A1 (en) | 2016-07-19 | 2018-01-25 | Duke University | Therapeutic applications of cpf1-based genome editing |
| US11883470B2 (en) | 2016-07-25 | 2024-01-30 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
| CN109715650B (en)* | 2016-07-26 | 2024-03-08 | 生物马林药物股份有限公司 | Novel adeno-associated viral capsid proteins |
| CN109640949B (en) | 2016-07-29 | 2022-11-25 | 加利福尼亚大学董事会 | Adeno-associated virus virions with variant capsids and methods of use thereof |
| MA55748A (en) | 2016-08-15 | 2022-03-02 | Genzyme Corp | AAV DETECTION METHODS |
| CN109996880A (en) | 2016-08-18 | 2019-07-09 | 加利福尼亚大学董事会 | CRISPR-CAS genome project based on modularization AAV delivery system |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| EP3518985A4 (en) | 2016-09-29 | 2020-08-05 | University of Florida Research Foundation, Incorporated | AAVRH.10 VARIANTS WITH EXIT OPTIONS FOR HOST ANTIBODIES AND CHANGED TISSUE TARGETING PROPERTIES |
| US11578340B2 (en) | 2016-10-13 | 2023-02-14 | University Of Massachusetts | AAV capsid designs |
| AU2017345470B2 (en) | 2016-10-19 | 2023-08-03 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| WO2018100054A1 (en) | 2016-12-01 | 2018-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of retinal degenerative diseases |
| US11584931B2 (en) | 2016-12-14 | 2023-02-21 | The J. David Gladstone Institutes | Methods and compositions for generating a deletion library and for identifying a defective interfering particle (DIP) |
| CA3048038A1 (en)* | 2016-12-30 | 2018-07-05 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating phenylketonuria |
| AU2018210326B9 (en) | 2017-01-20 | 2024-04-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Treatment of krabbe disease with umbilical cord blood transplantion (UCBT) and increased galactocerebrosidase (GALC) expression |
| JP2020510648A (en) | 2017-02-20 | 2020-04-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Gene therapy to treat familial hypercholesterolemia |
| JOP20190200A1 (en) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | Compositions useful in treatment of spinal muscular atrophy |
| PE20191362A1 (en) | 2017-02-28 | 2019-10-01 | Univ Pennsylvania | NEW VECTOR OF ADENO-ASSOCIATED VIRUS (AAV) SUBTYPE F AND USES OF IT |
| AU2018229293A1 (en) | 2017-02-28 | 2019-08-29 | Janssen Biotech, Inc. | Influenza vaccines based on AAV vectors |
| IL314284A (en) | 2017-03-01 | 2024-09-01 | Univ Pennsylvania | Gene therapy for ocular disorders |
| US11376321B2 (en) | 2017-03-02 | 2022-07-05 | Genethon | Method for removing anti-AAV antibodies from a blood-derived composition |
| EP3606544B1 (en) | 2017-04-05 | 2025-06-04 | University of Massachusetts | Minigene therapy |
| WO2018189208A1 (en) | 2017-04-10 | 2018-10-18 | Genethon | Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies |
| UY37679A (en) | 2017-04-14 | 2018-11-30 | Regenxbio Inc | TREATMENT OF MUCOPOLISACARIDOSIS II WITH IDURONATE-2-SULFATASE (IDS) HUMAN RECOMBINANT PRODUCED BY HUMAN NEURAL OR GLIAL CELLS |
| WO2018200542A1 (en) | 2017-04-24 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
| CN110913866A (en) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | Compositions and methods for treating Amyotrophic Lateral Sclerosis (ALS) |
| CN119491003A (en) | 2017-05-05 | 2025-02-21 | 沃雅戈治疗公司 | Compositions and methods for treating Huntington's disease |
| CA3059213A1 (en) | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
| BR112019023303A2 (en) | 2017-05-11 | 2020-06-16 | The Trustees Of The University Of Pennsylvania | GENE THERAPY FOR NEURONAL CEROID LIPOFUSCINOSES |
| CN108103058A (en)* | 2017-05-12 | 2018-06-01 | 北京五加和分子医学研究所有限公司 | A kind of gene therapy medicament of type-1 diabetes mellitus |
| EP3621982A4 (en) | 2017-05-12 | 2021-05-19 | University of Massachusetts | VIRAL VECTOR PRODUCTION |
| EP3630986A4 (en) | 2017-05-31 | 2021-08-11 | The Trustees of The University of Pennsylvania | GENE THERAPY FOR TREATMENT OF PEROXISOMAL DISEASES |
| US11680275B2 (en) | 2017-06-06 | 2023-06-20 | University Of Massachusetts | Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome |
| US11827898B2 (en) | 2017-06-14 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
| US10834136B2 (en) | 2017-06-15 | 2020-11-10 | Palo Alto Networks, Inc. | Access point name and application identity based security enforcement in service provider networks |
| US10721272B2 (en) | 2017-06-15 | 2020-07-21 | Palo Alto Networks, Inc. | Mobile equipment identity and/or IOT equipment identity and application identity based security enforcement in service provider networks |
| US10693918B2 (en) | 2017-06-15 | 2020-06-23 | Palo Alto Networks, Inc. | Radio access technology based security in service provider networks |
| US10812532B2 (en) | 2017-06-15 | 2020-10-20 | Palo Alto Networks, Inc. | Security for cellular internet of things in mobile networks |
| US10708306B2 (en) | 2017-06-15 | 2020-07-07 | Palo Alto Networks, Inc. | Mobile user identity and/or SIM-based IoT identity and application identity based security enforcement in service provider networks |
| US11050789B2 (en) | 2017-06-15 | 2021-06-29 | Palo Alto Networks, Inc. | Location based security in service provider networks |
| JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CA3068286A1 (en)* | 2017-06-22 | 2018-12-27 | Board Of Regents, The University Of Texas System | Methods for producing regulatory immune cells and uses thereof |
| CA3053154A1 (en) | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsids and methods of use thereof |
| KR20240063170A (en) | 2017-07-06 | 2024-05-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Aav9-mediated gene therapy for treating mucopolysaccharidosis type i |
| US11596698B2 (en) | 2017-07-07 | 2023-03-07 | Genethon | Synthetic polynucleotides encoding a human FKRP protein |
| WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| AU2018311069A1 (en) | 2017-08-03 | 2020-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| AU2018315127B2 (en) | 2017-08-07 | 2021-12-23 | Nbe-Therapeutics Ag | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| JP2020534788A (en)* | 2017-08-28 | 2020-12-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Adeno-associated virus capsid mutant and how to use it |
| KR20200052333A (en) | 2017-09-20 | 2020-05-14 | 4디 몰레큘러 테라퓨틱스 아이엔씨. | Adeno-associated viral variant capsids and uses thereof |
| US11739330B2 (en) | 2017-09-22 | 2023-08-29 | University Of Massachusetts | SOD1 dual expression vectors and uses thereof |
| MY205041A (en) | 2017-09-22 | 2024-09-29 | Genzyme Corp | Variant rnai |
| JP7449223B2 (en) | 2017-09-22 | 2024-03-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Gene therapy to treat mucopolysaccharidosis type II |
| CA3075656A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| CN112501208A (en)* | 2017-10-03 | 2021-03-16 | 普利维尔治疗公司 | Gene therapy for lysosomal disorders |
| TW202413649A (en) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | Treatment of amyotrophic lateral sclerosis (als) |
| US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| AU2018350992A1 (en) | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| MX2020003945A (en) | 2017-10-18 | 2020-11-09 | Regenxbio Inc | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap. |
| WO2019079632A1 (en) | 2017-10-18 | 2019-04-25 | Board Of Regents, The University Of Texas System | Glutaminase inhibitor therapy |
| AU2018372235B9 (en) | 2017-11-27 | 2022-03-10 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
| SG11202004991SA (en) | 2017-11-30 | 2020-06-29 | Univ Pennsylvania | Gene therapy for mucopolysaccharidosis iiib |
| AU2018375164B2 (en) | 2017-11-30 | 2025-05-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for Mucopolysaccharidosis IIIA |
| WO2019126329A1 (en) | 2017-12-19 | 2019-06-27 | Akouos Llc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| MX2020008133A (en) | 2018-02-01 | 2020-10-14 | Homology Medicines Inc | ADENO-ASSOCIATED VIRUS COMPOSITIONS TO RESTORE PAH GENE FUNCTION AND METHODS OF USE THEREOF. |
| US11306329B2 (en) | 2018-02-19 | 2022-04-19 | City Of Hope | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
| WO2019173434A1 (en) | 2018-03-06 | 2019-09-12 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
| JP2021519065A (en) | 2018-03-23 | 2021-08-10 | ユニバーシティ オブ マサチューセッツ | Gene therapy to treat bone disorders |
| JP7406677B2 (en) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | Viral vectors that evade antibodies |
| CA3094465A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| AU2019247746B2 (en) | 2018-04-03 | 2024-08-15 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| WO2019200016A1 (en) | 2018-04-10 | 2019-10-17 | President And Fellows Of Harvard College | Aav vectors encoding clarin-1 or gjb2 and uses thereof |
| US11981892B2 (en) | 2018-04-16 | 2024-05-14 | University Of Massachusetts | Compositions and methods for improved gene editing |
| CA3098448A1 (en) | 2018-04-27 | 2019-10-31 | University Of Massachusetts | Aav capsids identified by in vivo library selection |
| CA3098565A1 (en) | 2018-04-29 | 2019-11-07 | Claire G. ZHANG | Scalable clarification process for recombinant aav production |
| EP3788165A1 (en) | 2018-04-29 | 2021-03-10 | REGENXBIO Inc. | Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles |
| WO2019217582A1 (en) | 2018-05-08 | 2019-11-14 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
| WO2019217513A2 (en) | 2018-05-09 | 2019-11-14 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
| TW202005978A (en) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | Novel liver targeting adeno-associated viral vectors |
| EP3793616A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| BR112020023082A2 (en) | 2018-05-15 | 2021-02-09 | Voyager Therapeutics, Inc. | compositions and methods for the treatment of parkinson's disease |
| EP3793615A2 (en) | 2018-05-16 | 2021-03-24 | Voyager Therapeutics, Inc. | Directed evolution of aav to improve tropism for cns |
| WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
| EP3802829A4 (en) | 2018-06-08 | 2022-10-19 | University of Massachusetts | Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US12060567B2 (en) | 2018-06-13 | 2024-08-13 | Voyager Therapeutics, Inc. | Engineered untranslated regions (UTR) for AAV production |
| JP7385603B2 (en) | 2018-06-14 | 2023-11-22 | リジェネクスバイオ インコーポレイテッド | Anion exchange chromatography for recombinant AAV production |
| JP7565218B2 (en) | 2018-07-02 | 2024-10-10 | ボイジャー セラピューティクス インコーポレイテッド | Treatment of amyotrophic lateral sclerosis and spinal cord related disorders |
| GB201811368D0 (en) | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
| CN112512596A (en) | 2018-07-12 | 2021-03-16 | 火箭制药有限公司 | Gene therapy vectors for treating DANON disease |
| SG11202100139VA (en) | 2018-07-17 | 2021-02-25 | Neuromyon Inc | Treatment of neuropathy with dna constructs expressing igf-1 isoforms |
| CA3107462A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| JPWO2020026968A1 (en)* | 2018-07-30 | 2021-08-12 | 株式会社遺伝子治療研究所 | Method of enhancing gene expression by AAV vector |
| AR114540A1 (en) | 2018-08-03 | 2020-09-16 | Genzyme Corp | RNAi VARIANT VS a-SINUCLEIN |
| CN112567027A (en) | 2018-08-10 | 2021-03-26 | 再生生物股份有限公司 | Scalable methods for recombinant AAV production |
| BR112021003897A2 (en) | 2018-08-30 | 2021-05-25 | Tenaya Therapeutics, Inc. | reprogramming of cardiac cells with myocarin and asci1 |
| WO2020069339A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Mutant reverse tetracycline transactivators for expression of genes |
| SG11202103151RA (en) | 2018-09-28 | 2021-04-29 | Voyager Therapeutics Inc | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CA3113472A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| US12274733B2 (en) | 2018-09-28 | 2025-04-15 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| WO2020072354A1 (en) | 2018-10-01 | 2020-04-09 | The Trustees Of The University Of Pennsylvania | Compositions useful for treating gm1 gangliosidosis |
| TW202035689A (en) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | Methods for measuring the titer and potency of viral vector particles |
| WO2020072844A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| JP2022504740A (en) | 2018-10-12 | 2022-01-13 | ジェンザイム・コーポレーション | Generation of improved human PAHs for the treatment of severe PKU by gene replacement therapy directed to the liver |
| TW202028468A (en) | 2018-10-15 | 2020-08-01 | 美商航海家醫療公司 | Expression vectors for large-scale production of raav in the baculovirus/sf9 system |
| UY38407A (en) | 2018-10-15 | 2020-05-29 | Novartis Ag | TREM2 STABILIZING ANTIBODIES |
| CA3115524A1 (en) | 2018-10-15 | 2020-04-23 | Win Den Cheung | Methods for measuring the infectivity of replication defective viral vectors and viruses |
| WO2020086627A1 (en) | 2018-10-22 | 2020-04-30 | University Of Rochester | Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas9 fusion protein |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| TW202033224A (en) | 2018-11-16 | 2020-09-16 | 日商安斯泰來製藥股份有限公司 | Method for treating muscular dystrophy by targeting utrophin gene |
| AU2019381776A1 (en)* | 2018-11-16 | 2021-07-01 | AskBio Inc. | Therapeutic adeno-associated virus for treating Pompe disease |
| US20220033824A1 (en) | 2018-11-29 | 2022-02-03 | University Of Massachusetts | Modulation of sptlc1 via recombinant adeno-associated vectors |
| US20220089670A1 (en) | 2018-12-28 | 2022-03-24 | University Of Rochester | Gene Therapy for BEST1 Dominant Mutations |
| PT3906066T (en) | 2019-01-04 | 2024-02-06 | Ultragenyx Pharmaceutical Inc | Gene therapy constructs for treating wilson disease |
| CA3126481A1 (en) | 2019-01-14 | 2020-07-23 | University Of Rochester | Targeted nuclear rna cleavage and polyadenylation with crispr-cas |
| MX2021008542A (en) | 2019-01-18 | 2021-11-12 | Voyager Therapeutics Inc | Methods and systems for producing aav particles. |
| KR20210130158A (en) | 2019-01-31 | 2021-10-29 | 오레곤 헬스 앤드 사이언스 유니버시티 | Methods Using Transcription-Dependent Directed Evolution of AAV Capsids |
| WO2020172537A1 (en) | 2019-02-22 | 2020-08-27 | University Of Massachusetts | Oxr1 gene therapy |
| EP3927381A1 (en) | 2019-02-22 | 2021-12-29 | The Trustees of The University of Pennsylvania | Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration |
| WO2020174369A2 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
| KR20210132109A (en) | 2019-02-25 | 2021-11-03 | 유니버시티 오브 매사추세츠 | DNA-binding domain transactivators and uses thereof |
| CR20210444A (en) | 2019-02-25 | 2021-11-02 | Novartis Ag | COMPOSITIONS AND METHODS FOR TREATING BIETTI CRYSTALLINE DYSTROPHY |
| WO2020176562A1 (en) | 2019-02-26 | 2020-09-03 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of krabbe disease |
| CN113557010A (en) | 2019-02-28 | 2021-10-26 | 瑞泽恩制药公司 | Adeno-associated viral vectors for delivery of therapeutic agents |
| SG11202110146VA (en) | 2019-03-21 | 2021-10-28 | Stridebio Inc | Recombinant adeno-associated virus vectors |
| CA3130196A1 (en) | 2019-03-25 | 2020-10-01 | Isabelle Richard | Production of large-sized quasidystrophins using overlapping aav vectors |
| JP7630176B2 (en) | 2019-04-01 | 2025-02-17 | テナヤ セラピューティクス， インコーポレイテッド | Adeno-associated viruses with engineered capsids |
| SG11202110789VA (en) | 2019-04-03 | 2021-10-28 | Regenxbio Inc | Gene therapy for eye pathologies |
| TW202102526A (en) | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | Recombinant adeno-associated viruses and uses thereof |
| HUE064411T2 (en) | 2019-04-11 | 2024-03-28 | Regenxbio Inc | Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions |
| AU2020258483A1 (en) | 2019-04-17 | 2021-11-11 | Evox Therapeutics, Ltd. | Compositions of exosomes and AAV |
| TW202332458A (en) | 2019-04-19 | 2023-08-16 | 美商銳進科斯生物股份有限公司 | Adeno-associated virus vector formulations and methods |
| AU2020262416A1 (en) | 2019-04-24 | 2021-12-16 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| US20220315948A1 (en) | 2019-04-26 | 2022-10-06 | President And Fellows Of Harvard College | Aav vectors encoding mini-pcdh15 and uses thereof |
| AU2020264976A1 (en)* | 2019-04-29 | 2021-11-11 | The Trustees Of The University Of Pennsylvania | Novel AAV capsids and compositions containing same |
| EP3962536A1 (en) | 2019-04-29 | 2022-03-09 | Voyager Therapeutics, Inc. | Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors |
| AU2020270421A1 (en) | 2019-05-03 | 2021-11-18 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| EP3976631A1 (en)* | 2019-05-24 | 2022-04-06 | Regeneron Pharmaceuticals, Inc. | Modified viral particles and uses thereof |
| BR112021023899A2 (en) | 2019-05-28 | 2022-01-18 | Astellas Pharma Inc | Method for the treatment of muscular dystrophy by targeting the dmpk gene |
| EP3987024A4 (en) | 2019-06-20 | 2023-11-01 | University Of Massachusetts | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING |
| EP3994253A1 (en) | 2019-07-02 | 2022-05-11 | M6P Therapeutics (Switzerland) LLC | Vector compositions and methods of using same for treatment of lysosomal storage disorders |
| EP3997225A1 (en) | 2019-07-10 | 2022-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
| WO2021007515A1 (en) | 2019-07-11 | 2021-01-14 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with micrornas and other factors |
| FI3997214T3 (en) | 2019-07-11 | 2023-11-02 | Centre Nat Rech Scient | Chemically modified adeno-associated virus |
| US10557149B1 (en)* | 2019-07-15 | 2020-02-11 | Vigene Biosciences, Inc. | Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus |
| US10653731B1 (en)* | 2019-07-15 | 2020-05-19 | Vigene Biosciences Inc. | Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency |
| WO2021016453A1 (en) | 2019-07-23 | 2021-01-28 | University Of Rochester | Targeted rna cleavage with crispr-cas |
| WO2021021674A1 (en) | 2019-07-26 | 2021-02-04 | Akouos, Inc. | Methods of treating hearing loss using a secreted target protein |
| WO2021021661A1 (en) | 2019-07-26 | 2021-02-04 | Regenxbio Inc. | Engineered nucleic acid regulatory element and methods of uses thereof |
| US20220290182A1 (en) | 2019-08-09 | 2022-09-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| AU2020330121A1 (en)* | 2019-08-14 | 2022-03-03 | University Of Florida Research Foundation, Incorporated | AAV capsid variants for gene therapy |
| TW202122582A (en) | 2019-08-26 | 2021-06-16 | 美商航海家醫療公司 | Controlled expression of viral proteins |
| KR20220051246A (en) | 2019-08-26 | 2022-04-26 | 리젠엑스바이오 인크. | Treatment of diabetic retinopathy with fully human post-translational modified anti-VEGF Fab |
| AU2020337919A1 (en) | 2019-08-27 | 2022-03-24 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of disorders associated with repetitive DNA |
| WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN114555814A (en) | 2019-09-13 | 2022-05-27 | 罗特格斯新泽西州立大学 | AAV-compatible laminin-linker polymerin |
| CA3149449A1 (en) | 2019-09-19 | 2021-03-25 | Evelyne GICQUEL | Gene therapy expression system alleviating cardiac toxicity of fkrp |
| WO2021062092A1 (en) | 2019-09-26 | 2021-04-01 | Massachusetts Institute Of Technology | Trans-activated functional rna by strand displacement and uses thereof |
| WO2021062096A1 (en) | 2019-09-26 | 2021-04-01 | Massachusetts Institute Of Technology | Microrna-based logic gates and uses thereof |
| US20220347298A1 (en) | 2019-10-04 | 2022-11-03 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| AU2020362119A1 (en) | 2019-10-07 | 2022-05-26 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| EP4045665A4 (en) | 2019-10-15 | 2023-11-15 | University of Massachusetts | Rna editor-enhanced rna trans-splicing |
| CN118221785A (en)* | 2019-10-16 | 2024-06-21 | 上海药明康德新药开发有限公司 | Novel AAV variants |
| KR20220083714A (en) | 2019-10-17 | 2022-06-20 | 스트라이드바이오 인코포레이티드 | Adeno-associated viral vectors for the treatment of Niemann-Pick disease type C |
| US20230340078A1 (en) | 2019-11-14 | 2023-10-26 | Biomarin Pharmaceutical Inc. | Treatment of hereditary angioedema with liver-specific gene therapy vectors |
| WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
| WO2021108755A2 (en) | 2019-11-28 | 2021-06-03 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| EP4072595A1 (en) | 2019-12-10 | 2022-10-19 | Takeda Pharmaceutical Company Limited | Adeno associated virus vectors for the treatment of hunter disease |
| WO2021138559A1 (en) | 2019-12-31 | 2021-07-08 | Swanbio Therapeutics Limited | Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn) |
| TW202140791A (en) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | Methods of treating phenylketonuria |
| KR20220131522A (en) | 2020-01-22 | 2022-09-28 | 리젠엑스바이오 인크. | Treatment of Mucopolysaccharide I with Fully-Human Glycosylated Human Alpha-L-iduronidase (IDUA) |
| WO2021154956A1 (en) | 2020-01-29 | 2021-08-05 | Regenxbio Inc. | Treatment of mucopolysaccharidosis iva |
| WO2021154963A1 (en) | 2020-01-29 | 2021-08-05 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells |
| WO2021154839A1 (en) | 2020-01-30 | 2021-08-05 | Umoja Biopharma, Inc. | Bispecific transduction enhancer |
| EP4096721A1 (en) | 2020-02-02 | 2022-12-07 | The Trustees of The University of Pennsylvania | Compositions useful for treating gm1 gangliosidosis |
| CN115335526B (en) | 2020-02-07 | 2025-04-18 | 罗切斯特大学 | Ribozyme-mediated RNA assembly and expression |
| EP4100424A2 (en) | 2020-02-07 | 2022-12-14 | University of Rochester | Targeted translation of rna with crispr-cas13 to enhance protein synthesis |
| BR112022015921A2 (en) | 2020-02-14 | 2022-10-04 | Ultragenyx Pharmaceutical Inc | GENE THERAPY TO TREAT CDKL5 DEFICIENCY DISORDER |
| JP2023518327A (en)* | 2020-02-25 | 2023-04-28 | チルドレンズ・メディカル・リサーチ・インスティテュート | Adeno-associated virus capsid polypeptides and vectors |
| JP2023515672A (en) | 2020-03-02 | 2023-04-13 | テナヤ セラピューティクス， インコーポレイテッド | Gene vector regulation by cardiomyocyte-expressed microRNA |
| JP2023519344A (en) | 2020-03-27 | 2023-05-10 | ユニバーシティ オブ ロチェスター | CRISPR-Cas13 crRNA array |
| JP2023519307A (en) | 2020-03-27 | 2023-05-10 | ユニバーシティ オブ ロチェスター | Targeted destruction of viral RNA by CRISPR-CAS13 |
| WO2021191424A1 (en) | 2020-03-27 | 2021-09-30 | UCB Biopharma SRL | Autonomous knob domain peptides |
| AU2021248577A1 (en) | 2020-03-31 | 2022-09-29 | Sichuan Univeristy | AAV capsids variants and uses thereof |
| US20230129893A1 (en) | 2020-03-31 | 2023-04-27 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating propionic acidemia |
| TW202144575A (en) | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | Treatment of phenylketonuria with aav and therapeutic formulations |
| KR20220167324A (en) | 2020-04-10 | 2022-12-20 | 솔라 바이오사이언시즈 엘엘씨 | Compositions and methods for the treatment of protein aggregation disorders |
| JP2023523401A (en) | 2020-04-15 | 2023-06-05 | ボイジャー セラピューティクス インコーポレイテッド | Tau binding compound |
| WO2021222168A2 (en) | 2020-04-28 | 2021-11-04 | Sola Biosciences Llc | Compositions and methods for the treatment of tdp-43 proteinopathies |
| MX2022014258A (en) | 2020-05-12 | 2023-02-22 | Univ Pennsylvania | Compositions for drg-specific reduction of transgene expression. |
| US20230210941A1 (en) | 2020-05-12 | 2023-07-06 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of krabbe disease |
| WO2021231538A2 (en) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
| WO2021231567A2 (en) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions and methods for treating slc26a4-associated hearing loss |
| WO2021230385A1 (en) | 2020-05-15 | 2021-11-18 | Astellas Pharma Inc. | Method for treating muscular dystrophy by targeting utrophin gene |
| TW202208632A (en) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| CN116096737A (en) | 2020-06-05 | 2023-05-09 | 索拉生物科学有限公司 | Compositions and methods for treating synucleinopathies |
| US20230220069A1 (en) | 2020-06-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| US20230256117A1 (en) | 2020-06-19 | 2023-08-17 | Genethon | Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg |
| IL299333A (en) | 2020-06-24 | 2023-02-01 | Bioverativ Therapeutics Inc | Methods for the purification of viral vectors |
| EP4179096A1 (en) | 2020-07-10 | 2023-05-17 | Genethon | A novel muscle-specific promoter |
| EP4179091A1 (en) | 2020-07-10 | 2023-05-17 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Methods and compositions for treating epilepsy |
| IL299762A (en) | 2020-07-13 | 2023-03-01 | Univ Pennsylvania | Compositions useful for treatment of charcot-marie-tooth disease |
| AU2021307447A1 (en) | 2020-07-15 | 2023-03-09 | University Of Rochester | Targeted RNA cleavage with dCas13-RNase fusion proteins |
| WO2022017630A1 (en) | 2020-07-23 | 2022-01-27 | Ucl Business Ltd | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF |
| IL299928A (en) | 2020-07-27 | 2023-03-01 | Voyager Therapeutics Inc | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2022026410A2 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| CN116209430A (en) | 2020-08-07 | 2023-06-02 | 阿米库斯治疗学公司 | Vesicle targeting proteins and uses thereof |
| BR112023001852A2 (en) | 2020-08-07 | 2023-02-23 | Spacecraft Seven Llc | PLACOPHYLLIN-2 (PKP2) GENE THERAPY USING AAV VECTOR |
| CN114075610B (en)* | 2020-08-11 | 2023-11-17 | 北京荷塘生华医疗科技有限公司 | Universal primer for detecting wild adeno-associated virus and application thereof |
| JP2023537625A (en) | 2020-08-14 | 2023-09-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Novel AAV capsids and compositions containing them |
| AR123288A1 (en) | 2020-08-19 | 2022-11-16 | Stridebio Inc | ADENO ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF RETT SYNDROME |
| BR112023003310A2 (en) | 2020-08-24 | 2023-05-02 | Univ Pennsylvania | VIRAL VECTORS ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND THEIR USES IN THE TREATMENT OF METABOLIC DISEASES |
| GB202013194D0 (en) | 2020-08-24 | 2020-10-07 | Combigene Ab | Gene therapy for lipodystrophy |
| JP2023540054A (en) | 2020-08-26 | 2023-09-21 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Recombinant adeno-associated virus for the treatment of GRN-associated adult-onset neurodegeneration |
| TW202218686A (en) | 2020-09-09 | 2022-05-16 | 美商維泰克斯製藥公司 | Compositions and methods for treatment of duchenne muscular dystrophy |
| CN116323641A (en) | 2020-09-10 | 2023-06-23 | 路德维希-马克西米利安慕尼黑大学 | Engineered AAV vectors |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| EP4214242A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized antibodies for anti-viral therapy |
| EP4213890A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized lanadelumab and administration thereof |
| US20230383278A1 (en) | 2020-09-18 | 2023-11-30 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency |
| WO2022066849A1 (en) | 2020-09-24 | 2022-03-31 | University Of Massachusetts | Aav vectors encoding nf1 and uses thereof |
| AU2021355481A1 (en) | 2020-10-01 | 2023-06-08 | Genzyme Corporation | Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy |
| JP2023544803A (en) | 2020-10-07 | 2023-10-25 | レジェンクスバイオ インコーポレーテッド | Gene therapy for ocular symptoms of CLN2 disease |
| JP2023545424A (en) | 2020-10-07 | 2023-10-30 | リジェネックスバイオ インコーポレイテッド | Preparations for suprachoroidal administration, such as gel preparations |
| IL301647A (en) | 2020-10-07 | 2023-05-01 | Regenxbio Inc | Adeno-associated viruses for ocular delivery of gene therapy |
| TW202228649A (en) | 2020-10-07 | 2022-08-01 | 美商銳進科斯生物股份有限公司 | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| WO2022076750A2 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns or muscle delivery |
| WO2022076549A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as high viscosity formulations |
| US11781156B2 (en) | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
| US20230365955A1 (en) | 2020-10-09 | 2023-11-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| US20230383313A1 (en) | 2020-10-18 | 2023-11-30 | The Trustees Of The University Of Pennsylvania | Improved adeno-associated virus (aav) vector and uses therefor |
| WO2022094078A1 (en) | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| CA3195967A1 (en) | 2020-10-28 | 2022-05-05 | Xu Wang | Vectorized anti-tnf-? antibodies for ocular indications |
| WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
| US20230390418A1 (en) | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| US20240384292A1 (en) | 2020-10-29 | 2024-11-21 | Regenxbio Inc. | Vectorized tnf-alpha antagonists for ocular indications |
| WO2022098933A1 (en) | 2020-11-06 | 2022-05-12 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of dm1 with slucas9 and sacas9 |
| CN112322791B (en)* | 2020-11-27 | 2023-10-27 | 福建省农业科学院畜牧兽医研究所 | Novel duck dependent genus virus loop-mediated isothermal amplification detection primer set and kit |
| JP2023551911A (en) | 2020-12-01 | 2023-12-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Compositions and uses thereof for the treatment of Angelman syndrome |
| KR20230117157A (en) | 2020-12-01 | 2023-08-07 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Novel composition having a tissue-specific targeting motif and composition comprising the same |
| PE20240115A1 (en) | 2020-12-01 | 2024-01-22 | Akouos Inc | CONSTRUCTIONS OF ANTI-VEGF ANTIBODIES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SCHWANNOMA |
| AU2021403076A1 (en) | 2020-12-16 | 2023-06-29 | Regenxbio Inc. | Method of producing a recombinant adeno-associated virus particle |
| AU2021412962A1 (en) | 2020-12-29 | 2023-08-17 | Akouos, Inc. | Compositions and methods for treating clrn1-associated hearing loss and/or vision loss |
| WO2022147087A1 (en) | 2020-12-29 | 2022-07-07 | Regenxbio Inc. | Tau-specific antibody gene therapy compositions, methods and uses thereof |
| WO2022155500A1 (en) | 2021-01-14 | 2022-07-21 | Senti Biosciences, Inc. | Secretable payload regulation |
| JP2024503895A (en) | 2021-01-21 | 2024-01-29 | リジェネクスバイオ インコーポレイテッド | Improving the production of recombinant polypeptides and viruses |
| EP4281559A4 (en) | 2021-01-22 | 2024-12-04 | University of Massachusetts | USE OF NOVEL MIRNA BINDING SITE CASSETTES FOR TARGETING ANTIGEN-PRESENTING CELLS FROM TRANSGENE EXPRESSION BY RAAV GENE THERAPY VECTORS |
| MX2023008831A (en) | 2021-01-27 | 2023-10-19 | Umoja Biopharma Inc | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor. |
| MX2023008826A (en) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Gene therapy for neuronal ceroid lipofuscinoses. |
| MX2023009118A (en) | 2021-02-10 | 2023-10-18 | Regenxbio Inc | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids). |
| GB202101958D0 (en) | 2021-02-12 | 2021-03-31 | Ucl Business Ltd | Gene therapy for dopamine transporter deficiency syndrome |
| TW202246510A (en) | 2021-02-26 | 2022-12-01 | 美商維泰克斯製藥公司 | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9 |
| JP2024509792A (en) | 2021-02-26 | 2024-03-05 | 武田薬品工業株式会社 | Compositions and methods for the treatment of Fabry disease |
| EP4298222A1 (en) | 2021-02-26 | 2024-01-03 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9 |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| US20240141377A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| EP4314303A2 (en) | 2021-03-22 | 2024-02-07 | Genzyme Corporation | Size exclusion chromatography analysis of empty and full aav capsids |
| US20240165271A1 (en) | 2021-03-26 | 2024-05-23 | The Board Of Regents Of The University Of Texas System | Nucleotide editing to reframe dmd transcripts by base editing and prime editing |
| US20240191258A1 (en) | 2021-04-12 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Compositions useful for treating spinal and bulbar muscular atrophy (sbma) |
| JP2024515715A (en) | 2021-04-23 | 2024-04-10 | ユニバーシティ オブ ロチェスター | Methods for genome editing and therapy by directed heterologous DNA insertion using retroviral integrase-Cas fusion proteins |
| CA3216004A1 (en) | 2021-04-23 | 2022-10-27 | The Trustees Of The University Of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
| WO2022229851A1 (en) | 2021-04-26 | 2022-11-03 | Crispr Therapeutics Ag | Compositions and methods for using slucas9 scaffold sequences |
| BR112023021999A2 (en) | 2021-04-26 | 2023-12-26 | Regenxbio Inc | ADMINISTRATION OF MICRODYSTROPHIN GENE THERAPY FOR THE TREATMENT OF DYSTROPHINOPATHIES |
| US20240218397A1 (en) | 2021-05-04 | 2024-07-04 | Regenxbio Inc. | Novel aav vectors and methods and uses thereof |
| WO2022234519A1 (en) | 2021-05-05 | 2022-11-10 | Crispr Therapeutics Ag | Compositions and methods for using sacas9 scaffold sequences |
| US20240358857A1 (en) | 2021-05-11 | 2024-10-31 | Regenxbio Inc. | Treatment of duchenne muscular dystrophy and combinations thereof |
| KR20240025645A (en) | 2021-06-25 | 2024-02-27 | 옥스포드 바이오메디카 솔루션즈 엘엘씨 | Adeno-Associated Virus Packaging System |
| EP4362957A1 (en) | 2021-07-01 | 2024-05-08 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| EP4363437A1 (en) | 2021-07-01 | 2024-05-08 | Amicus Therapeutics, Inc. | Neurotensin variants and tagged proteins comprising neurotensin or sortilin propeptide |
| IL309742A (en) | 2021-07-08 | 2024-02-01 | Tenaya Therapeutics Inc | Optimized expression cassettes for gene therapy |
| EP4373947A1 (en) | 2021-07-19 | 2024-05-29 | New York University | Auf1 combination therapies for treatment of muscle degenerative disease |
| WO2023010133A2 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
| AU2022318664A1 (en) | 2021-07-30 | 2024-02-29 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
| WO2023018637A1 (en) | 2021-08-09 | 2023-02-16 | Vertex Pharmaceuticals Incorporated | Gene editing of regulatory elements |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| WO2023019229A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| AU2022340808B2 (en) | 2021-08-31 | 2024-08-08 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| EP4399302A2 (en) | 2021-09-08 | 2024-07-17 | Vertex Pharmaceuticals Incorporated | Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy |
| PE20241065A1 (en) | 2021-09-30 | 2024-05-13 | Akouos Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEARING LOSS ASSOCIATED WITH KCNQ4 |
| EP4408481A2 (en) | 2021-10-01 | 2024-08-07 | BioMarin Pharmaceutical Inc. | Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations |
| TW202325845A (en) | 2021-10-02 | 2023-07-01 | 賓州大學委員會 | Novel aav capsids and compositions containing same |
| CN118202060A (en) | 2021-10-05 | 2024-06-14 | 再生生物股份有限公司 | Compositions and methods for recombinant AAV production |
| WO2023060113A1 (en) | 2021-10-05 | 2023-04-13 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2023060269A1 (en) | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for targeted delivery |
| WO2023060272A2 (en) | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
| CA3234720A1 (en) | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of p53-mediated cancers |
| EP4413024A2 (en) | 2021-10-08 | 2024-08-14 | SOLA Biosciences LLC | Compositions and methods for the treatment of proteopathies |
| CA3234231A1 (en) | 2021-10-21 | 2023-04-27 | Vertex Pharmaceuticals Incorporated | Hypoimmune cells |
| US20250025574A1 (en) | 2021-10-28 | 2025-01-23 | Regenxbio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
| WO2023087019A2 (en) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| KR20240126860A (en) | 2021-11-30 | 2024-08-21 | 재규어 진 테라피, 엘엘씨 | Gene therapy method for treating diabetes |
| WO2023102517A1 (en) | 2021-12-02 | 2023-06-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| KR20240126864A (en) | 2021-12-17 | 2024-08-21 | 타팔지 세러퓨틱스 | Peptides and methods for use in pain treatment |
| EP4442698A1 (en) | 2021-12-28 | 2024-10-09 | Chengdu Origen Biotechnology Co., Ltd. | Modified aav capsid protein and use thereof |
| US20250084129A1 (en)* | 2022-01-10 | 2025-03-13 | University Of Florida Research Foundation, Incorporated | Aav5 capsid variants |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250177495A1 (en) | 2022-01-10 | 2025-06-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
| AR128239A1 (en) | 2022-01-10 | 2024-04-10 | Univ Pennsylvania | COMPOSITIONS AND USEFUL METHODS FOR THE TREATMENT OF DISORDERS MEDIATED BY C9ORF72 |
| EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
| IL314434A (en) | 2022-01-25 | 2024-09-01 | Univ Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| JP2025506349A (en) | 2022-02-02 | 2025-03-11 | アコーオス インコーポレイテッド | Anti-VEGF antibody constructs and related methods for treating vestibular schwannoma-associated conditions |
| TW202346599A (en) | 2022-02-08 | 2023-12-01 | 美商航海家醫療公司 | Aav capsid variants and uses thereof |
| WO2023156530A1 (en) | 2022-02-17 | 2023-08-24 | Lysogene | Gene therapy for neurodegenerative diseases |
| CN119032102A (en) | 2022-02-17 | 2024-11-26 | 萨那生物技术股份有限公司 | Engineered CD47 proteins and their uses |
| WO2023172927A1 (en) | 2022-03-08 | 2023-09-14 | Vertex Pharmaceuticals Incorporated | Precise excisions of portions of exon 44, 50, and 53 for treatment of duchenne muscular dystrophy |
| EP4490291A1 (en) | 2022-03-08 | 2025-01-15 | Vertex Pharmaceuticals Incorporated | Precise excisions of portions of exons for treatment of duchenne muscular dystrophy |
| WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
| TW202346590A (en) | 2022-03-13 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | Modified muscle-specific promoters |
| WO2023183623A1 (en) | 2022-03-25 | 2023-09-28 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| EP4504950A1 (en) | 2022-04-01 | 2025-02-12 | Takeda Pharmaceutical Company Limited | Gene therapy for diseases with cns manifestations |
| WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
| TW202404651A (en) | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| WO2023196892A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
| JP2025512969A (en) | 2022-04-06 | 2025-04-22 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Compositions and methods for treating her2 positive metastatic breast cancer and other cancers |
| KR20240169111A (en) | 2022-04-06 | 2024-12-02 | 젠자임 코포레이션 | Targeted gene therapy for DM-1 myotonic dystrophy |
| JP2025512962A (en) | 2022-04-06 | 2025-04-22 | リジェネックスバイオ インコーポレイテッド | Pharmaceutical compositions comprising recombinant adeno-associated viral vectors carrying an expression cassette encoding a transgene for suprachoroidal administration |
| TW202345913A (en) | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | Formulations for suprachoroidal administration such as gel formulations |
| WO2023198652A1 (en) | 2022-04-11 | 2023-10-19 | Centre National De La Recherche Scientifique | Chemically-modified adeno-associated viruses |
| JP2025512333A (en) | 2022-04-11 | 2025-04-17 | テナヤ セラピューティクス， インコーポレイテッド | Adeno-associated viruses with engineered capsids |
| CN119365208A (en) | 2022-04-13 | 2025-01-24 | 巴塞罗那自治大学 | Treating neuromuscular diseases by gene therapy expressing KLOTHO protein |
| WO2023201308A1 (en) | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Gene therapy for treating an ocular disease |
| WO2023201277A1 (en) | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
| TW202405173A (en) | 2022-04-18 | 2024-02-01 | 美商維泰克斯製藥公司 | Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver |
| WO2023215806A2 (en) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
| WO2023215807A1 (en) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS |
| EP4519463A1 (en) | 2022-05-06 | 2025-03-12 | Novartis AG | Novel recombinant aav vp2 fusion polypeptides |
| AR129441A1 (en) | 2022-05-25 | 2024-08-28 | Tafalgie Therapeutics | PEPTIDES AND METHODS FOR PAIN TREATMENT |
| WO2023239627A2 (en) | 2022-06-08 | 2023-12-14 | Regenxbio Inc. | Methods for recombinant aav production |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| AU2023289696A1 (en) | 2022-06-24 | 2025-01-16 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
| WO2024006770A1 (en)* | 2022-06-27 | 2024-01-04 | Astellas Gene Therapies, Inc. | Compositions and methods for the treatment of myotonic dystrophies |
| EP4547690A1 (en) | 2022-06-28 | 2025-05-07 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| CN120051297A (en) | 2022-06-30 | 2025-05-27 | 因达普塔治疗公司 | Combination of engineered natural killer (NK) cells and antibody therapy and related methods |
| WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| EP4554967A2 (en) | 2022-07-12 | 2025-05-21 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
| EP4558634A1 (en) | 2022-07-18 | 2025-05-28 | Vertex Pharmaceuticals Incorporated | Tandem guide rnas (tg-rnas) and their use in genome editing |
| WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| CN115354049A (en)* | 2022-07-29 | 2022-11-18 | 中国科学院深圳先进技术研究院 | Application of a gene delivery system in delivering target gene to liver via intravenous injection |
| WO2024044725A2 (en) | 2022-08-24 | 2024-02-29 | Regenxbio Inc. | Recombinant adeno-associated viruses and uses thereof |
| WO2024042485A1 (en) | 2022-08-25 | 2024-02-29 | Takeda Pharmaceutical Company Limited | Composition for use in the treatment of fabry disease |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| TW202417631A (en) | 2022-09-22 | 2024-05-01 | 美商拜奧馬林製藥公司 | Treatment of cardiomyopathy with aav gene therapy vectors |
| TW202421788A (en) | 2022-09-22 | 2024-06-01 | 美商拜奧馬林製藥公司 | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
| AU2023354256A1 (en) | 2022-09-30 | 2025-04-10 | AbbVie Global Enterprises Ltd. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
| WO2024081746A2 (en) | 2022-10-11 | 2024-04-18 | Regenxbio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
| WO2024105638A1 (en) | 2022-11-18 | 2024-05-23 | Jcr Pharmaceuticals Co., Ltd. | Recombinant aav vectors and methods for treatment of hunter syndrome |
| TW202440939A (en) | 2022-12-17 | 2024-10-16 | 賓州大學委員會 | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| IT202200026595A1 (en) | 2022-12-22 | 2024-06-22 | Fond Telethon Ets | NEW INHIBITORS OF EPIGENETIC REGULATORS |
| US12252518B2 (en) | 2023-01-06 | 2025-03-18 | Life Biosciences, Inc. | Methods of treating non-arteritic anterior ischemic optic neuropathy |
| WO2024146935A1 (en) | 2023-01-06 | 2024-07-11 | Institut National de la Santé et de la Recherche Médicale | Intravenous administration of antisense oligonucleotides for the treatment of pain |
| WO2024151541A1 (en) | 2023-01-09 | 2024-07-18 | Sana Biotechnology, Inc. | Type-1 diabetes autoimmune mouse |
| WO2024149844A1 (en) | 2023-01-12 | 2024-07-18 | Nantes Université | Chemically-modified adeno-associated virus |
| WO2024163683A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist) |
| WO2024163678A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods |
| WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024161032A1 (en) | 2023-02-03 | 2024-08-08 | Janssen Pharmaceutica Nv | Gene therapy vectors for use in parkinson's disease |
| GB202302480D0 (en) | 2023-02-22 | 2023-04-05 | Drishti Discoveries Ltd | shRNA for the treatment of disease |
| WO2024192281A2 (en) | 2023-03-15 | 2024-09-19 | Regenxbio Inc. | Exon skipping gene therapy constructs, vectors and uses thereof |
| WO2024196855A2 (en) | 2023-03-17 | 2024-09-26 | University Of Rochester | Ribozyme-mediated rna assembly and expression |
| WO2024211780A1 (en) | 2023-04-07 | 2024-10-10 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2024215655A1 (en) | 2023-04-10 | 2024-10-17 | Tenaya Therapeutics, Inc. | Cardioprotective bag3 therapies |
| WO2024215653A1 (en) | 2023-04-10 | 2024-10-17 | Tenaya Therapeutics, Inc. | Guide rnas, vectors, and virions for targeting mutations in the pln gene |
| CN116622908B (en)* | 2023-04-13 | 2024-02-06 | 武汉珈创生物技术股份有限公司 | Primer probe, kit and method for rapidly detecting wild adeno-associated virus and application |
| WO2024216244A2 (en) | 2023-04-13 | 2024-10-17 | Regenxbio Inc. | Targeting aav capsids, methods of manufacturing and using same |
| WO2024224361A1 (en) | 2023-04-26 | 2024-10-31 | Sanofi | Host cell lines and methods for identifying and using such host cell lines |
| WO2024228938A1 (en)* | 2023-05-01 | 2024-11-07 | St. Jude Children's Research Hospital, Inc. | Modified aav p5 promoter for improved vector titer and purity |
| WO2024229302A1 (en) | 2023-05-03 | 2024-11-07 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| US20240401025A1 (en) | 2023-05-03 | 2024-12-05 | Manifold Biotechnologies, Inc. | Methods and compositions for high-throughput protein delivery, screening, and detection |
| WO2024233529A2 (en) | 2023-05-07 | 2024-11-14 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2024233791A1 (en) | 2023-05-11 | 2024-11-14 | Seelos Therapeutics, Inc. | Methods of treating neurodegenerative disorders |
| WO2024238859A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
| WO2024238867A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| WO2024238853A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Adeno-associated viruses for ocular delivery of gene therapy |
| WO2024243236A2 (en) | 2023-05-22 | 2024-11-28 | Sana Biotechnology, Inc. | Methods of delivery of islet cells and related methods |
| WO2024241176A1 (en) | 2023-05-24 | 2024-11-28 | Jcr Pharmaceuticals Co., Ltd. | Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders |
| WO2024243563A1 (en) | 2023-05-25 | 2024-11-28 | Juno Therapeutics, Inc. | Aav purification method |
| WO2024258961A1 (en) | 2023-06-12 | 2024-12-19 | The Trustees Of The University Of Pennsylvania | Aav gene therapy for mucopolysaccharidosis iiib |
| WO2025007046A1 (en) | 2023-06-29 | 2025-01-02 | The Trustees Of The University Of Pennsylvania | Mutant aav with central nervous system targeting motifs and compositions containing same |
| WO2025008406A1 (en) | 2023-07-04 | 2025-01-09 | Institut National de la Santé et de la Recherche Médicale | Antisense oligonucleotides and their use for the treatment of cancer |
| WO2025017168A1 (en) | 2023-07-19 | 2025-01-23 | Genethon | Novel optimized utrophin micro-genes |
| WO2025017169A1 (en) | 2023-07-20 | 2025-01-23 | Genethon | Novel mididystrophins |
| WO2025035143A1 (en) | 2023-08-10 | 2025-02-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of spinal muscular atrophy |
| WO2025038430A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2025072604A1 (en) | 2023-09-28 | 2025-04-03 | University Of Rochester | Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1) |
| WO2025075963A1 (en) | 2023-10-02 | 2025-04-10 | Regenxbio Inc. | Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase |
| WO2025080780A1 (en) | 2023-10-10 | 2025-04-17 | University Of Rochester | Delivery and expression of prime editing crispr systems |
| WO2025090962A1 (en) | 2023-10-25 | 2025-05-01 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2025090858A1 (en) | 2023-10-27 | 2025-05-01 | Biogen Ma Inc. | Methods for identifying aav capsid variants with desired characteristics |
| WO2025102034A1 (en) | 2023-11-10 | 2025-05-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
| WO2025106374A1 (en) | 2023-11-13 | 2025-05-22 | Juno Therapeutics, Inc. | Aav production method |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
| WO2025108407A2 (en) | 2023-11-23 | 2025-05-30 | Neuexcell Therapeutics (Suzhou) Co., Ltd. | Gene therapy compositions and methods for treating glioma |
| WO2025113676A1 (en) | 2023-11-29 | 2025-06-05 | Neuexcell Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treating stroke in primates |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
| WO2025128817A1 (en) | 2023-12-15 | 2025-06-19 | Genzyme Corporation | Artificial micrornas targeting tau |
| CN118459608B (en)* | 2024-04-26 | 2025-01-24 | 泰州博莱得利生物科技有限公司 | Canine parvovirus specific immune preparation, preparation method and application |
| CN118460614B (en)* | 2024-07-05 | 2025-03-11 | 凌意(杭州)生物科技有限公司 | Expression frame of adeno-associated virus Cap protein |